FDA & drugs

FDA Approves Cemdisiran, the First siRNA Drug for Myasthenia Gravis, Given Every 3 Months

A C5-silencing RNA drug given every three months beat placebo on daily function in the 284-patient NIMBLE trial, and it carries a boxed warning for meningococcal infection.

AI-generated image

The FDA approved cemdisiran (Livsayis) on Nov. 18, 2026, for adults with generalized myasthenia gravis who carry acetylcholine receptor (AChR) antibodies, Regeneron said. The company calls it the first siRNA therapy for the disease, injected under the skin every three months.

For students, the approval adds a new mechanism to a core neurology topic: instead of an antibody that blocks complement protein C5, an RNA drug stops the liver from making it. For residents, it brings a boxed warning for meningococcal infection, a restricted-access program and a vaccine deadline before the first dose.

Livsayis is No. 55 on the FDA's 2026 novel drug approvals list. It came five days after No. 50, Klygefa (gefurulimab), which the agency approved on Nov. 13 for the same AChR antibody-positive form of the disease.

284 patients, four arms and a 2.3-point edge on daily function

The approval rests on NIMBLE, a randomized, double-blind, placebo-controlled phase 3 trial at 86 centers in 13 countries, published in The Lancet by Tuan Vu of the University of South Florida and colleagues. As of a July 8, 2025, data cut-off, 284 patients had been randomly assigned to one of four arms for 24 weeks:

  • Cemdisiran alone: 600 mg every 12 weeks (79 patients).
  • Pozelimab alone: a C5 antibody, 200 mg every 4 weeks (50 patients).
  • Both drugs: cemdisiran 200 mg plus pozelimab 200 mg, each every 4 weeks (80 patients).
  • Placebo (75 patients).

On the primary endpoint, the Myasthenia Gravis Activities of Daily Living (MG-ADL) score, cemdisiran patients improved by 4.5 points at week 24, versus 2.2 points with placebo. The placebo-adjusted difference was 2.3 points (p=0.0005). The combination arm improved by 4.0 points, a numerically smaller gain than cemdisiran alone.

Regeneron reported that 76.6% of cemdisiran patients gained at least 3 MG-ADL points, versus 44.1% on placebo. On the clinician-scored Quantitative Myasthenia Gravis (QMG) scale, the placebo-adjusted gain was 2.8 points (p=0.0015).

Vu, the trial's global principal investigator, said in the company's release that the drug "delivered rapid, deep disease control." Regeneron says improvement appeared as early as two weeks.

The cost of switching off C5: a meningococcal warning

Cemdisiran is a small interfering RNA (siRNA) directed at C5 that lowers the amount of C5 protein in the blood, Regeneron says. An antibody such as pozelimab binds C5; cemdisiran cuts the supply. An editorial in Med called it the first complement inhibitor for myasthenia gravis to use this mechanism. Regeneron develops and sells the drug under a worldwide license from Alnylam.

Losing C5 activity has a known cost. Deficiencies in the late complement proteins that build the membrane attack complex are associated with meningococcal infections, StatPearls notes. Livsayis carries a Boxed Warning for serious meningococcal infections, plus warnings for other encapsulated bacteria, including Streptococcus pneumoniae, Haemophilus influenzae and Neisseria gonorrhoeae.

The drug is available only through a Risk Evaluation and Mitigation Strategy (REMS). Regeneron's safety information says meningococcal vaccines must be completed at least two weeks before the first dose; if treatment must start right away, the vaccines should be given as soon as possible.

In NIMBLE, no serious or meningococcal infections occurred in the cemdisiran group during the double-blind period, the Lancet authors reported. The most common adverse reactions were injection site reactions, viral infections and urinary tract infections, according to Regeneron.

What to know for exams and the wards

  • Who it is for. The FDA wording covers anti-AChR antibody-positive disease, which Regeneron calls the predominant form; it estimates about 85,000 people in the U.S. have myasthenia gravis. NIMBLE also enrolled patients with anti-LRP4 antibodies, but the approved use names only AChR.
  • Sort the drug classes. A 2026 review in Neurology and Therapy groups targeted therapy into complement inhibitors (eculizumab, ravulizumab, zilucoplan, gefurulimab and cemdisiran), neonatal Fc receptor (FcRn) blockers (efgartigimod, rozanolixizumab and nipocalimab) and B-cell therapies (rituximab and inebilizumab).
  • Put the vaccine before the prescription. For Livsayis, meningococcal vaccination is due at least two weeks before the first dose, so it belongs in the plan from the first conversation.
  • Link it to the physiology. In AChR-positive disease, autoantibodies switch on complement, and that drives the damage, the NIMBLE investigators write. Newer drugs either inhibit complement, as cemdisiran does, or lower overall antibody levels.

What we don't know yet

  • How it compares. No head-to-head trials compare the newer myasthenia gravis drugs, the Neurology and Therapy review notes.
  • Whether the field needed another. Linda Kusner and Henry Kaminski of George Washington University asked in Med whether cemdisiran is "NIMBLE enough," noting three complement inhibitors were already FDA-approved for the disease. They wrote before Klygefa's approval.
  • Long-term safety. NIMBLE is still ongoing. Two deaths occurred after the double-blind period; the investigator judged one treatment-related and the sponsor did not, the paper reports. Regeneron funded the trial.
  • Price and timing. Regeneron did not state a U.S. price or launch date. A European decision is expected in the second half of 2027.

Neurology shelf reviews are in MedRise Board Review, including the acute stroke algorithm. Our Nov. 20 story covered venglustat for Gaucher type 3, approved the same day. More resources are on the residents page.

For decades, myasthenia gravis care leaned on steroids and broad immunosuppression. The newer question is which step of the immune attack to switch off, and how often a patient has to come back for it; cemdisiran's answer is four times a year.

The MedRise Briefing

Medicine’s changes, explained before they hit you

New Perspectives, USMLE, Match and ECFMG updates and the medical news that matters to students and residents, in one short monthly email. Free, no spam.

Use a personal email, not a school one, so it keeps reaching you after you graduate or change schools.

By subscribing, you agree to get the MedRise Briefing, one email a month. Unsubscribe anytime with one click. We never sell your email. Privacy

Work in medicine and have a view on stories like this?

Write it up for MedRise Perspectives: 600 to 1,200 words, published under your name, with a decision usually within one day.